Wednesday, October 8, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Medicine

Breakthrough Blood Test for ME/Chronic Fatigue Syndrome Unveiled

October 8, 2025
in Medicine
Reading Time: 4 mins read
0
blank
65
SHARES
592
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

A groundbreaking development in the diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has emerged from a collaborative research project between the University of East Anglia (UEA) and Oxford BioDynamics. These scientists have successfully engineered a blood test with remarkable accuracy to diagnose ME/CFS, a complex and debilitating illness that affects millions worldwide and has long evaded reliable diagnostic techniques. The blood test reportedly achieves a diagnostic accuracy of 96 percent, offering new hope to patients who often experience protracted misdiagnosis or dismissal of their symptoms.

ME/CFS, characterized by profound and persistent fatigue not alleviated by rest, significantly impairs quality of life. Despite its prevalence, including over 400,000 known cases in the United Kingdom alone, the condition has remained poorly understood in clinical settings due to the absence of definitive diagnostic markers. Patients frequently report skepticism from healthcare professionals and delays in receiving appropriate care, exacerbating the burden of this chronic illness.

Professor Dmitry Pshezhetskiy from UEA’s Norwich Medical School, who led the study, emphasized the pressing need for objective diagnostic tools. He explained that the new test could fundamentally alter the clinical approach to ME/CFS by providing a tangible biomarker for diagnosis. Early and accurate identification could enable timely interventions, personalized management strategies, and reduce the psychological toll on patients who are often stigmatized or dismissed.

The innovative blood test leverages Oxford BioDynamics’ proprietary EpiSwitch® 3D Genomics platform. This advanced technology interrogates the three-dimensional folding patterns of DNA within blood cells. While our genetic code is linear and fixed, the spatial configuration of the genome—the epigenome—modulates gene activity dynamically, responding to environmental and physiological cues. By analyzing these complex 3D genomic structures, researchers can identify epigenetic markers indicative of disease states.

In this study, blood samples from 47 individuals diagnosed with severe ME/CFS and 61 healthy controls were subjected to comprehensive EpiSwitch® analysis. This approach revealed distinctive and reproducible DNA folding signatures exclusive to ME/CFS patients, forming the basis for the test’s diagnostic criteria. The epigenetic markers identified are not embedded in the genetic code itself but reflect regulatory changes that influence immune function and inflammatory pathways implicated in ME/CFS pathology.

Alexandre Akoulitchev, Chief Scientific Officer at Oxford BioDynamics, highlighted that ME/CFS is fundamentally an acquired condition rather than a congenital genetic disorder. Therefore, detecting dynamic epigenetic changes is superior to traditional genetic screening for diagnosis. The EpiSwitch® platform’s capability to dissect precise 3D genomic alterations enables rapid and scalable diagnostic assessments, distinguishing it from other blood test modalities.

Significantly, the test demonstrated 92 percent sensitivity, meaning it reliably identified individuals with ME/CFS, and an impressive 98 percent specificity, effectively excluding individuals without the disease. This high degree of accuracy surpasses existing diagnostic methods, which rely heavily on symptom-based criteria and often lead to false positives or negatives. Such precision paves the way for confident clinical decision-making and personalized patient management.

Beyond diagnostic utility, the analysis unearthed molecular insights into the biological pathways active in ME/CFS. The researchers pinpointed disruptions in immune system regulation and chronic inflammatory responses, consistent with the hypothesized immunological underpinnings of the illness. These findings not only enhance understanding of ME/CFS but also suggest potential targets for therapeutic intervention and patient stratification according to molecular profiles.

The implications of this research extend into the emergent field of post-viral syndromes, particularly long Covid. ME/CFS-like symptom clusters have been observed following SARS-CoV-2 infection, often termed post-Covid syndrome. The researchers propose that the EpiSwitch® test framework could be adapted to detect similar epigenetic signatures in long Covid patients, facilitating early diagnosis and tailored treatment approaches in this expanding clinical challenge.

Historically, Oxford BioDynamics’ EpiSwitch® technology has proven successful in identifying disease-specific biomarkers in other complex conditions, including rapidly progressing neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), autoimmune diseases like rheumatoid arthritis, and various cancers. Notably, the EpiSwitch® PSE test for prostate cancer has already achieved global recognition for its diagnostic accuracy, underscoring the platform’s broad applicability and clinical impact.

This breakthrough represents a paradigm shift in ME/CFS research and clinical practice, transcending traditional genetic analyses such as the DecodeME initiative. While DecodeME focused on linear genomic sequencing to uncover hereditary risk loci, the current work pioneers a complementary approach by mapping dynamic 3D genomic structures, uncovering hundreds of additional disease-associated changes. This integrated genomic and epigenomic perspective promises more comprehensive disease characterization.

The study’s authors advocate for the integration of the EpiSwitch® CFS blood test into routine clinical diagnostic protocols for ME/CFS, offering a tool that is both practical and scalable within healthcare systems. This advance is poised to reduce diagnostic delays, increase patient validation, and foster development of targeted therapeutics, heralding a new era in the management of this challenging chronic disease.

Published in the esteemed Journal of Translational Medicine, this research exemplifies the power of cutting-edge genomic technologies to unravel complex disease mechanisms and translate bench-side discoveries into clinical innovations. It signals hope to millions grappling with ME/CFS and lays foundational work towards addressing the diagnostic voids that have long confounded patients and clinicians alike.

The research was a concerted effort by UEA, Oxford BioDynamics, the London School of Hygiene & Tropical Medicine, and the Royal Cornwall Hospitals NHS Trust. Their collective expertise and technological innovation have delivered a much-needed, objective diagnostic instrument that promises to transform patient outcomes and stimulate further investigation into the molecular biology of ME/CFS and long Covid.

Subject of Research: Human tissue samples
Article Title: ‘Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling’
News Publication Date: 8-Oct-2025
Web References: https://www.94percent.com/
References: DecodeME genetic study on ME/CFS
Keywords: COVID 19, Diseases and disorders, Clinical medicine, Medical diagnosis, Medical tests

Tags: accurate ME/CFS testingbiomarkers for Chronic Fatigue Syndromebreakthrough in ME/CFS researchChronic Fatigue Syndrome blood testdiagnostic accuracy in chronic illnesseshealthcare professional skepticismimproving quality of life for chronic illness patientsMyalgic Encephalomyelitis diagnosisOxford BioDynamics collaborationpatient care in ME/CFSpersonalized management for ME/CFSUniversity of East Anglia study
Share26Tweet16
Previous Post

Young Scientists Honored with $250,000 Prizes at Blavatnik National Awards Gala

Next Post

KDM4B Regulates ERα in Vascular Cell Calcification

Related Posts

blank
Medicine

Questionnaires for Assessing Patient Preferences in Consultations

October 8, 2025
blank
Medicine

Puberty Timing Linked to PAH-Alb Adducts Levels

October 8, 2025
blank
Medicine

KDM4B Regulates ERα in Vascular Cell Calcification

October 8, 2025
blank
Medicine

Calorie Labeling Associated with 2% Average Decrease in Menu Item Energy Content

October 7, 2025
blank
Medicine

New Study Finds Commonly Prescribed Opioid Tramadol Less Effective for Chronic Pain Relief

October 7, 2025
blank
Medicine

Short bursts of exercise could enhance cardiorespiratory fitness in inactive adults, study finds

October 7, 2025
Next Post
blank

KDM4B Regulates ERα in Vascular Cell Calcification

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27564 shares
    Share 11022 Tweet 6889
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    972 shares
    Share 389 Tweet 243
  • Bee body mass, pathogens and local climate influence heat tolerance

    646 shares
    Share 258 Tweet 162
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    514 shares
    Share 206 Tweet 129
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    480 shares
    Share 192 Tweet 120
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Questionnaires for Assessing Patient Preferences in Consultations
  • Puberty Timing Linked to PAH-Alb Adducts Levels
  • Shared Brain and Molecular Links in Diabetes, Depression
  • KDM4B Regulates ERα in Vascular Cell Calcification

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,186 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading